Patients with T2D and overweight/obesity starting GLP-1 therapy may experience a small but statistically significant increase ...

In patients with T2D, the risks for gastroesophageal reflux disease and related complications are greater with GLP-1 RA ...

USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...

Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk ...

Taiwan: A recent study has found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type ...

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

This 3-part series looks at the current evidence for the treatment of SUDs. Part 2 reviews the use of GLP-1 receptor agonists and alcohol use disorder.

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors, according to data presented at the EULAR ...

Addressing obesity and fibromyalgia are essential components to managing the most complex patients with psoriatic arthritis, ...

Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitors (single agonists such as semaglutide) and also dual glucose-dependent ...

Two main types of autoimmune pancreatitis (AIP) have been described: type 1, linked to IgG4-related disease, and type 2, associated with inflammatory bowel diseases. Recently, a third type has been ...

Hanmi Pharmaceutical's "Efeglenatide," the first domestically developed GLP-1 (glucagon-like peptide-1) obesity drug in Korea, is set to expand its ...